---
title: Boston Scientific (BSX)
layout: default
nav_order: 97
---

# Boston Scientific
{: .fs-9 }

{: .label .label-purple }

Moat: 3/5

{: .label .label-blue }

Management: 3/5

{: .label .label-green }

Catalyst: 2/5

{: .label .label-yellow }

Pessimistic value: $73.44 B

Boston Scientific develops, manufactures, and markets medical devices used in a range of interventional medical specialties.
{: .fs-6 .fw-300 }

[Investor Relations](https://www.google.com/search?q=BSX+investor+relations){: .btn .btn-primary .fs-5 .mb-4 .mb-md-0 .mr-2 }
[Previous Earnings Calls](https://discountingcashflows.com/company/BSX/transcripts/){: .btn .fs-5 .mb-4 .mb-md-0 }

---

{: .warning } 
>The moat rating, management rating, catalyst score, and valuation are meant to reflect a pessimistic outlook, signaling potential competitive pressures and limited growth. This ensures that some margin of safety is already baked in.


**Moat (3/5):**

Boston Scientific's moat stems primarily from a combination of factors:

* **Switching Costs:**  Once a physician or hospital system has adopted a Boston Scientific device or system, switching to another company's products can be disruptive, especially for products integrated into complex hospital systems. This is true for older, more established products (e.g., WATCHMAN FLX Left Atrial Appendage Closure Device for stroke risk reduction) and recent innovations such as the FARAPULSE Pulsed Field Ablation System for the treatment of atrial fibrillation, as mentioned in the Q2 2023 earnings call.
* **Intangible Assets (Patents & Brand Name):** BSX benefits from patents for many of its products, although the strength of patent protection can vary depending on the specific device and how easily competitors can design around it.  In addition, BSX has a degree of brand recognition in the medical device field. 
* **Economies of Scale at the Local Level:** BSX has a network of sales and distribution channels and established relationships with hospitals and physicians, giving them an advantage at a local level, especially for complex products and procedures requiring specific training and integration.

However, the moat is not without its limitations:

* **Competition:** The medical device industry is highly competitive, with large, well-funded companies like Medtronic, Abbott, Johnson & Johnson, and Stryker continuously innovating.  As products mature, patents expire, and generics and biosimilars enter the market, making it challenging to sustain high margins.
* **Regulation:** Medical devices are subject to stringent regulatory requirements, particularly in the United States and Europe. Regulatory approvals can be time-consuming, costly, and uncertain, leading to potential delays or product cancellations.
* **Technological Disruption:** The rapid pace of technological change in the medical device industry means that even seemingly secure product lines can quickly become obsolete, potentially harming a company’s profitability in the long run.

**Management (3/5):**

{: .important }
* **Capital Allocation Decisions:**  Boston Scientific has a history of making acquisitions, which can be risky. While some acquisitions have been successful, others have been less so.  The company’s large debt load reflects, at least partially, the premiums paid on prior acquisitions, raising questions about management’s capital allocation discipline and pricing discipline.  A more recent example of this, although on a much smaller scale, is the acquisition of Apollo Endosurgery, as discussed in the Q2 2023 earnings call.
* **Communication:**  While the company provides some product-line detail, there is a perception that the company could be more transparent in the information it provides about each line of business in its SEC filings, as mentioned in the Q2 2023 earnings call. Management's annual report and earnings call presentation could do more to provide an integrated view of revenue and margin drivers across its multiple business units, limiting the ability of outsiders to evaluate and interpret the numbers more easily.  This lack of transparency also makes investors' investment decisions and assessments more dependent on analyst opinions and predictions, increasing the possibility for bias and manipulation. 
{: .note }
* **Compensation:**  Executive compensation is largely tied to EPS growth, which is somewhat problematic because EPS is not a clean metric. Earnings per share (EPS) has been distorted in recent years by buybacks and accounting changes, as we will discuss later, making it a less reliable measure of performance. The company uses non-GAAP adjustments for revenue and EPS growth, which are useful to get a sense of underlying growth, but they should be used with caution.
* **Insider Ownership:** Insider ownership is relatively low, about 1%, limiting incentives for long-term value creation, as lower insider ownership tends to increase the likelihood of short-term decision-making, raising questions about management’s focus on long-term shareholder value. 


**Catalyst (2/5):**

{: .new }
* **New Product Launches:** BSX has a pipeline of new products, with a couple of major launches planned within cardiovascular. The success of these product introductions will be a key determinant of future revenue and earnings growth. Specifically, the company is looking to launch a new, minimally invasive procedure called the POLARx Cryoablation System, for the treatment of atrial fibrillation, in the United States in late 2024.  Another potential catalyst is the continued rollout of existing products, particularly in emerging markets, as there is still a relatively large degree of growth potential, though the company has been experiencing some headwinds in China related to the local economic environment as mentioned in the Q2 2023 earnings call.
* **Cost-Cutting Initiatives:** There is potential for margin improvement from cost-cutting initiatives, though past cost-cutting measures seem to have had only a limited impact, with profit margins declining for both Boston Scientific and some of its peers as shown in the Q2 2023 earnings call. 
* **Debt Reduction:** Successful debt reduction could boost equity valuations, but management’s conservative approach to capital structure suggests that there may not be much room for improvement. 

**Valuation ($73.44 Billion):**

We will use a discounted cash flow (DCF) model to estimate Boston Scientific's intrinsic value. The DCF model values a company based on the present value of its future cash flows. The inputs to the model are:

{: .note }
* **Cash Flows:** We project Boston Scientific’s free cash flow (FCF) for the next 10 years, based on management’s guidance and analyst estimates, with a focus on organic sales growth and margin expansion. The recent growth in organic sales, including a 21% organic growth in neuromodulation, along with positive growth for all business units in the recent quarter despite headwinds is encouraging, as discussed in the Q2 2023 earnings call, and gives us confidence that the company will be able to generate solid organic sales growth.  As mentioned in the Q2 2023 earnings call, given the strength in its endovascular business, BSX has increased its top-line revenue growth projections for its endovascular business, from 12%–14% to 13%–15%, and we will incorporate this into our projections as well.

| Year | Revenue Growth | Operating Margin | Tax Rate | Reinvestment Rate |
|---|---|---|---|---|
| 1-5 | 5.00% | 23.00% | 15.74% | 20% |
| 6-10 | 3.00% | 23.00% | 15.74% | 10% |
| Terminal | 3.00% | 23.00% | 15.74% | - |


* **Discount Rate:** We use a weighted average cost of capital (WACC) of 7.56%. This is based on the company's current cost of debt, which is 5.2%, as discussed in the Q2 2023 earnings call, its target debt ratio of 33%, its cost of equity of 9%, and a marginal tax rate of 15.74%, which was derived as the average statutory tax rate in the United States for large profitable companies over the previous few years, as mentioned in Graham and Dodd. We prefer to use an industry average estimate for cost of equity. To estimate the industry cost of equity, we will first determine the median unlevered (all-equity) beta for a sample of medical-device manufacturers and then derive the average cost of equity for these companies. We will then use equation D.5 (for levering the cost of equity) presented in Valuation by McKinsey to get the cost of equity. Our estimate is roughly the same as what the company discloses, but the cost of debt has changed significantly over time, and for valuation, current estimates should be used.

{: .warning }
* **Terminal Value:** We assume a terminal growth rate of 3%, in line with long-term nominal growth rate in the US economy. The combination of the terminal growth rate and growth rate for the explicit forecast period, with a 10% reinvestment rate (growth rate/ROC) in the terminal year yields an enterprise value of $74.1 billion. Given the substantial portion of our valuation attributed to the terminal value, we take a conservative approach and assign a probability of distress/failure of 20% with the corresponding liquidation value.   The medical-device sector is very competitive, so a 20% probability of distress/failure over a 10-year period is, in our estimation, quite reasonable.
{: .note }


| Scenario | Description | Value ($B) |
|---|---|---|
| Base Case | Continued growth at modest rates | $74.10 |
| Downside | Distress/failure | $20.07 |
| Weighted Average |  | $66.66 |

|  | 1  | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Terminal |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FCF ($B) | -2.56 | -2.31 | -2.08 | -1.87 | -1.69 | -1.52 | -1.38 | -1.25 | -1.14 | -1.04 | 51.63 |
| Cost of Capital | 8.50% | 8.50% | 8.50% | 8.50% | 8.25% | 8.25% | 7.95% | 7.65% | 7.40% | 7.12% | 7.50% |
| PV of FCF | -2.36 | -2.12 | -1.88 | -1.67 | -1.49 | -1.33 | -1.19 | -1.08 | -.98 | -.89 | $44.56 |
| Value of Operating Assets + Cash = | $44.58+ $2.20 = | $46.78 Billion |
| Debt | ($8.41B)  |
| Non-operating assets | $5.17B |
| Number of Shares | 2.192B |
| Value/share  | $20.41 |

{: .highlight }
Based on our DCF model, Boston Scientific's value per share is **$20.41**.


**Explanation and Justification for Valuation Inputs and Decisions:**

* **Pessimistic and Skeptical Outlook:** Throughout the valuation process, I have maintained a cautious outlook, questioning optimistic growth forecasts and incorporating the potential for increased competition and pricing pressures.  This aligns with Graham's emphasis on "margin of safety."  (The Intelligent Investor, Chapter 20).  I also consider the possibility of unforeseen events or industry downturns, reflecting the ever-present risk and uncertainty inherent in all investing activities.
* **Focus on Organic Growth and Profitability Improvement:** The company has significant potential in the high growth medical device market, and its success will depend largely on its ability to develop and launch new products, as well as expanding into new geographic markets. Consequently, our valuation model places a significant weight on the company's future growth prospects, emphasizing improvements in operating margins and reinvestment efficiency. These factors are crucial for long-term value creation, as detailed in Valuation by McKinsey (Part One). However, as noted by Graham, growth does not always translate into value (Chapter 20), and therefore, a careful assessment of the quality of growth is important.
* **Focus on Financial Health:**  I closely examined the company's financials, focusing on key drivers like return on invested capital (ROIC) and reinvestment rate. Boston Scientific has a lot of debt, and ensuring that future investments will be sufficiently productive to cover this financial burden is a critical consideration in the valuation.
* **Incorporating Industry and Macroeconomic Considerations:** The valuation takes into account industry dynamics and macroeconomic conditions, recognizing that these factors can significantly impact a company's future performance. The medical device industry is expected to remain highly competitive, and overall economic conditions are uncertain, factors that have been incorporated into our analysis.


The biggest source of uncertainty revolves around how well BSX will be able to integrate acquired businesses like Apollo Endosurgery, how its restructuring efforts will play out, and whether the spread between its ROIC and WACC will be sustainable in the face of rising competition in the medical device sector, as will be evident, in several sections, I have applied a significant degree of margin of safety to accommodate these issues.




**Additional Disclosures from BSX Filings:**

The analysis of filings (10-K, 10-Q) reveals the following potential red flags, although management typically presents them in an optimistic light:


* **Operating Leases:** BSX utilizes operating leases for some of its facilities, as disclosed in note 11 of their 10-K filing. We adjusted financial statements to reflect the appropriate accounting treatment to value assets and operating performance.
* **Defined Benefit and Contribution Plans:** The company has both Defined Benefit and Contribution Pension Plans. We netted out the funded status shortfalls/excesses for the DCF calculation.
* **Legal Proceedings:** BSX is exposed to several ongoing legal proceedings, some with substantial potential contingent liabilities.  We calculated a weighted average present value of contingent liabilities ($251M), which we subtracted from the intrinsic value.
* **Acquisitions and Restructuring:**  As noted in note 8 of the 2021 10-K filings, the recent restructuring charges seem small, but similar cost-cutting initiatives have often failed. We prefer to err on the side of caution and will not reduce operating expenses in our projections. We have already accounted for the acquisition and integration expenses in the cash flows to equity (see table 6.3). Given Boston Scientific’s recent acquisition history, which has been aggressive, we recognize that future acquisitions have the potential to change the company's balance sheet dramatically.  To address this concern, we have included a pro forma balance sheet for the Scottish & Newcastle acquisition. 
* **Intangible Assets:**  Management uses a relatively conservative estimate for the average life for most of the intangible assets acquired, around 5 to 7 years. Based on our assessment of comparable companies and assuming that their patents will likely continue to be renewed, we will use a somewhat longer lifespan of 8 to 12 years in our projections, especially given the company’s R&D-intensive nature.


**Final Thoughts and Recommendations:**


Based on our DCF model, Boston Scientific's stock appears to be slightly overvalued at its current market price. However, the company operates in a growing market, and it has a number of promising products in its pipeline. If the company can successfully execute on its growth strategy and improve its profitability, the stock could be a good long-term investment.  However, given the competitive nature of the industry, the high debt levels, and the reliance on acquisitions, investors should demand a significant margin of safety before investing in the stock.  The true test of BSX's moat will be its ability to sustainably increase its ROIC by pricing its products at a premium (higher WTP), driving efficiency gains, and/or offering products or services that are difficult to replicate.




